Fiercebiotech
Published November 17, 2026
Marrow extracts $120M series B for blood disease drug - Fierce Biotech
Read the full story at Fiercebiotech
The biotech's lead candidate, dubbed MAR-101, uses the ... Helus' chemically modified psychedelic hits key goals in phase 3 depression trial.
Surfaced by this Google Alert
- Psychedelic biotech